BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting Biotech Investing
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin Life Science Investing
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Life Science Investing
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1 -directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors Life Science Investing
NRx Pharmaceuticals Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality Life Science Investing
Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting Medical Device Investing
U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Pharmaceutical Investing
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026 Psychedelics Investing
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research Annual Meeting 2026 Life Science Investing
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 Life Science Investing
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products Psychedelics Investing
